Comparative study of pentoxifylline vs antiaggregants in patients with transient ischaemic attacks.
Out of 235 patients with recent cerebral transient ischaemic attacks, 208 subjects were available for final evaluation after 6 months' randomised treatment with either pentoxifylline (PTX 1200 mg/day) or a combination (ASAD) of acetylsalicylic acid (ASA, 1050 mg/day) and dipyridamole (D, 150 mg/day). Prevention of TIA, stroke or death attributable to previous events were endpoint criteria. The pentoxifylline group (n = 100) exhibited no recurrent episodes in 86 patients (86%). TIA occurred in 9 patients, stroke in 5 patients and there was 1 death. In the ASAD group (n = 108) no recurrence of ischaemic episodes was recorded in 82 cases (75.9%). TIA occurred in 20 patients, stroke in 6 patients and there were 3 deaths of vascular origin. Side effects were recorded in 4 ASAD and 1 PTX patients. The total rate of recurrence was 14% with PTX as compared to 24.1% with ASAD treatment.
Herskovits
E
E
Neurology Division of Hospitals Juan A. Fernández, Buenos Aires, Argentina.
Famulari
A
A
Tamaroff
L
L
Gonzalez
A M
AM
Vzquez
A
A
Dominguez
R
R
Fraiman
H
H
Vila
J
J
Benjamin
V
V
Matera
V
V
D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D004176:Dipyridamole / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010431:Pentoxifylline / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013805:Theobromine / Q000031:analogs & derivatives*
D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D013805:Theobromine; D001241:Aspirin; D010431:Pentoxifylline